Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inventiva S.A.

3.56
+0.20005.95%
Volume:30.01K
Turnover:103.62K
Market Cap:340.56M
PE:-1.12
High:3.61
Open:3.47
Low:3.26
Close:3.36
Loading ...

Company Profile

Company Name:
Inventiva S.A.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
116
Office Location:
50 rue de Dijon,Daix,Burgundy,France
Zip Code:
21121
Fax:
- -
Introduction:
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Directors

Name
Position
Frederic Cren
Chief Executive Officer and Chairman of the Board of Director
Pierre Broqua
Deputy Chief Executive Officer, Chief Scientific Officer and Director
Annick Schwebig
Director
Chris Buyse
Director
Heinz Maeusli
Director
Lucy Lu
Director
Nawal Ouzren
Director

Shareholders

Name
Position
Frederic Cren
Chief Executive Officer and Chairman of the Board of Director
Pierre Broqua
Deputy Chief Executive Officer, Chief Scientific Officer and Director
Jean Volatier
Chief Financial Officer
Marie Paule Richard
Chief Medical Officer